Acetylsalicylsalicylic acid, also known as diaspirin, is a synthetic derivative of salicylic acid. It is a prodrug that is hydrolyzed in the body to produce two molecules of aspirin. The compound is formed by reacting salicylic acid with acetic anhydride. Studies have shown that acetylsalicylsalicylic acid has similar pharmacological effects to aspirin, including analgesic, antipyretic, and anti-inflammatory properties. Its effects are attributed to its ability to inhibit the production of prostaglandins. Acetylsalicylsalicylic acid is studied for its potential therapeutic applications in conditions such as pain, fever, and inflammation. Its unique structure and the fact that it releases two molecules of aspirin upon hydrolysis make it an interesting subject for research. In addition to its pharmacological effects, acetylsalicylsalicylic acid is also studied for its potential as a prodrug delivery system for other active compounds. However, acetylsalicylsalicylic acid is not currently marketed as a drug and is primarily used in research settings.'
acetylsalicylsalicylic acid: potential immunogenic impurity in aspirin; structure [Medical Subject Headings (MeSH), National Library of Medicine, extracted Dec-2023]
| ID Source | ID |
|---|---|
| PubMed CID | 10745 |
| CHEMBL ID | 350343 |
| CHEBI ID | 94629 |
| SCHEMBL ID | 25398 |
| MeSH ID | M0048913 |
| Synonym |
|---|
| smr001233486 |
| MLS002154199 , |
| BRD-K46585355-001-05-1 |
| DIVK1C_006990 |
| c16h12o6 |
| SPECTRUM_001708 |
| PRESTWICK_544 , |
| acetylsalicylsalicylic acid |
| 530-75-6 |
| NCGC00016489-01 |
| cas-530-75-6 |
| SPECTRUM5_001849 |
| BSPBIO_002250 |
| BPBIO1_000062 |
| BSPBIO_000056 |
| PRESTWICK3_000098 |
| PRESTWICK2_000098 |
| AB00053270 |
| NCGC00095332-01 |
| einecs 208-493-6 |
| 2-carboxyphenyl o-acetylsalicylate |
| ccris 1740 |
| KBIO1_001934 |
| KBIO3_001470 |
| KBIOGR_001596 |
| KBIO2_004756 |
| KBIOSS_002188 |
| KBIO2_002188 |
| KBIO2_007324 |
| SPECTRUM2_001664 |
| SPECPLUS_000894 |
| PRESTWICK1_000098 |
| PRESTWICK0_000098 |
| SPBIO_001847 |
| SPECTRUM3_000725 |
| SPBIO_001995 |
| SPECTRUM4_001118 |
| SPECTRUM1504209 |
| 2-(2-acetyloxybenzoyl)oxybenzoic acid |
| CHEMBL350343 |
| 2-(2-methylcarbonyloxyphenylcarbonyloxy)benzoic acid |
| HMS1568C18 |
| HMS2095C18 |
| HMS2231N10 |
| AKOS016010380 |
| CCG-39089 |
| NCGC00016489-02 |
| vbe72mcp5l , |
| unii-vbe72mcp5l |
| benzoic acid, 2-(acetyloxy)-, 2-carboxyphenyl ester |
| 2-carboxyphenyl 2-(acetyloxy)benzoate |
| acesalum |
| 2-(acetyloxy)benzoic acid 2-carboxyphenyl ester |
| salicylacetylsalicylic acid |
| FT-0621819 |
| 2-((2-acetoxybenzoyl)oxy)benzoic acid |
| AB03877 |
| HMS3372D03 |
| acetylsalicylic acid impurity d [ep impurity] |
| acetylsalicylsalicylic acid [mi] |
| carbasalate calcium impurity b [ep impurity] |
| 2-((2-(acetyloxy)benzoyl)oxy)benzoic acid |
| 2-hydroxybenzoic acid acetate 2-carboxyphenyl ester |
| dl-lysine acetylsalicylate impurity l [ep impurity] |
| acetylsalicylsalicyic acid |
| SCHEMBL25398 |
| 2-{[2-(acetyloxy)benzoyl]oxy}benzoic acid |
| diplosalsalate |
| DS-2808 |
| 2-[2-(acetyloxy)benzoyloxy]benzoic acid |
| 2-([2-(acetyloxy)benzoyl]oxy)benzoic acid # |
| cid_10745 |
| bdbm66982 |
| 2-[(2-acetyloxyphenyl)-oxomethoxy]benzoic acid |
| 2-(2-acetyloxyphenyl)carbonyloxybenzoic acid |
| 2-(2-acetoxybenzoyl)oxybenzoic acid |
| DTXSID5074977 |
| mfcd00143537 |
| SR-01000841191-2 |
| sr-01000841191 |
| CHEBI:94629 |
| 2-[[2-(acetyloxy)benzoyl]oxy]benzoic acid (acetylsalicylsalicylic acid) |
| HMS3712C18 |
| 2-((2-acetoxybenzoyl)oxy)benzoicacid |
| 2-[(2-acetoxybenzoyl)oxy]benzoic acid |
| BCP07875 |
| aspirin impurity d |
| Q26840909 |
| aspirin impurity d; diplosal acetate; diplosalacetat; 2-(acetyloxy)benzoic acid 2-carboxyphenyl ester |
| BRD-K46585355-001-09-3 |
| STL193282 |
| 2-({[2-(acetyloxy)phenyl]carbonyl}oxy)benzoic acid |
| 2-(2-acetoxybenzoyloxy)benzoic acid |
| CS-0128732 |
| SY102057 |
| carbasalate impurity b |
| Class | Description |
|---|---|
| carbonyl compound | Any compound containing the carbonyl group, C=O. The term is commonly used in the restricted sense of aldehydes and ketones, although it actually includes carboxylic acids and derivatives. |
| [compound class information is derived from Chemical Entities of Biological Interest (ChEBI), Hastings J, Owen G, Dekker A, Ennis M, Kale N, Muthukrishnan V, Turner S, Swainston N, Mendes P, Steinbeck C. (2016). ChEBI in 2016: Improved services and an expanding collection of metabolites. Nucleic Acids Res] | |
| Protein | Taxonomy | Measurement | Average (µ) | Min (ref.) | Avg (ref.) | Max (ref.) | Bioassay(s) |
|---|---|---|---|---|---|---|---|
| Chain A, MAJOR APURINIC/APYRIMIDINIC ENDONUCLEASE | Homo sapiens (human) | Potency | 0.8437 | 0.0032 | 45.4673 | 12,589.2998 | AID2517 |
| Chain A, HADH2 protein | Homo sapiens (human) | Potency | 31.6228 | 0.0251 | 20.2376 | 39.8107 | AID893 |
| Chain B, HADH2 protein | Homo sapiens (human) | Potency | 31.6228 | 0.0251 | 20.2376 | 39.8107 | AID893 |
| Chain A, 2-oxoglutarate Oxygenase | Homo sapiens (human) | Potency | 31.6228 | 0.1778 | 14.3909 | 39.8107 | AID2147 |
| USP1 protein, partial | Homo sapiens (human) | Potency | 39.8107 | 0.0316 | 37.5844 | 354.8130 | AID504865 |
| cytochrome P450 2C9 precursor | Homo sapiens (human) | Potency | 15.8489 | 0.0063 | 6.9043 | 39.8107 | AID883 |
| chromobox protein homolog 1 | Homo sapiens (human) | Potency | 79.4328 | 0.0060 | 26.1688 | 89.1251 | AID540317 |
| geminin | Homo sapiens (human) | Potency | 0.5805 | 0.0046 | 11.3741 | 33.4983 | AID624297 |
| lamin isoform A-delta10 | Homo sapiens (human) | Potency | 0.3162 | 0.8913 | 12.0676 | 28.1838 | AID1487 |
| Rap guanine nucleotide exchange factor 3 | Homo sapiens (human) | Potency | 125.8920 | 6.3096 | 60.2008 | 112.2020 | AID720707 |
| Histamine H2 receptor | Cavia porcellus (domestic guinea pig) | Potency | 15.8489 | 0.0063 | 8.2350 | 39.8107 | AID883 |
| [prepared from compound, protein, and bioassay information from National Library of Medicine (NLM), extracted Dec-2023] | |||||||
| Protein | Taxonomy | Measurement | Average | Min (ref.) | Avg (ref.) | Max (ref.) | Bioassay(s) |
|---|---|---|---|---|---|---|---|
| Chain A, BCL-2-RELATED PROTEIN A1 | Homo sapiens (human) | EC50 (µMol) | 350.0000 | 8.0570 | 121.1218 | 338.0000 | AID2765 |
| bcl-2-like protein 11 isoform 1 | Homo sapiens (human) | EC50 (µMol) | 350.0000 | 8.0570 | 121.1218 | 338.0000 | AID2765 |
| [prepared from compound, protein, and bioassay information from National Library of Medicine (NLM), extracted Dec-2023] | |||||||
| Process | via Protein(s) | Taxonomy |
|---|---|---|
| guanyl-nucleotide exchange factor activity | Rap guanine nucleotide exchange factor 3 | Homo sapiens (human) |
| protein binding | Rap guanine nucleotide exchange factor 3 | Homo sapiens (human) |
| protein domain specific binding | Rap guanine nucleotide exchange factor 3 | Homo sapiens (human) |
| cAMP binding | Rap guanine nucleotide exchange factor 3 | Homo sapiens (human) |
| [Information is prepared from geneontology information from the June-17-2024 release] | ||
| Process | via Protein(s) | Taxonomy |
|---|---|---|
| plasma membrane | Rap guanine nucleotide exchange factor 3 | Homo sapiens (human) |
| cortical actin cytoskeleton | Rap guanine nucleotide exchange factor 3 | Homo sapiens (human) |
| plasma membrane | Rap guanine nucleotide exchange factor 3 | Homo sapiens (human) |
| microvillus | Rap guanine nucleotide exchange factor 3 | Homo sapiens (human) |
| endomembrane system | Rap guanine nucleotide exchange factor 3 | Homo sapiens (human) |
| membrane | Rap guanine nucleotide exchange factor 3 | Homo sapiens (human) |
| lamellipodium | Rap guanine nucleotide exchange factor 3 | Homo sapiens (human) |
| filopodium | Rap guanine nucleotide exchange factor 3 | Homo sapiens (human) |
| extracellular exosome | Rap guanine nucleotide exchange factor 3 | Homo sapiens (human) |
| [Information is prepared from geneontology information from the June-17-2024 release] | ||
| Assay ID | Title | Year | Journal | Article |
|---|---|---|---|---|
| AID651635 | Viability Counterscreen for Primary qHTS for Inhibitors of ATXN expression | |||
| AID588501 | High-throughput multiplex microsphere screening for inhibitors of toxin protease, specifically Lethal Factor Protease, MLPCN compound set | 2010 | Current protocols in cytometry, Oct, Volume: Chapter 13 | Microsphere-based flow cytometry protease assays for use in protease activity detection and high-throughput screening. |
| AID588501 | High-throughput multiplex microsphere screening for inhibitors of toxin protease, specifically Lethal Factor Protease, MLPCN compound set | 2006 | Cytometry. Part A : the journal of the International Society for Analytical Cytology, May, Volume: 69, Issue:5 | Microsphere-based protease assays and screening application for lethal factor and factor Xa. |
| AID588501 | High-throughput multiplex microsphere screening for inhibitors of toxin protease, specifically Lethal Factor Protease, MLPCN compound set | 2010 | Assay and drug development technologies, Feb, Volume: 8, Issue:1 | High-throughput multiplex flow cytometry screening for botulinum neurotoxin type a light chain protease inhibitors. |
| AID588497 | High-throughput multiplex microsphere screening for inhibitors of toxin protease, specifically Botulinum neurotoxin light chain F protease, MLPCN compound set | 2010 | Current protocols in cytometry, Oct, Volume: Chapter 13 | Microsphere-based flow cytometry protease assays for use in protease activity detection and high-throughput screening. |
| AID588497 | High-throughput multiplex microsphere screening for inhibitors of toxin protease, specifically Botulinum neurotoxin light chain F protease, MLPCN compound set | 2006 | Cytometry. Part A : the journal of the International Society for Analytical Cytology, May, Volume: 69, Issue:5 | Microsphere-based protease assays and screening application for lethal factor and factor Xa. |
| AID588497 | High-throughput multiplex microsphere screening for inhibitors of toxin protease, specifically Botulinum neurotoxin light chain F protease, MLPCN compound set | 2010 | Assay and drug development technologies, Feb, Volume: 8, Issue:1 | High-throughput multiplex flow cytometry screening for botulinum neurotoxin type a light chain protease inhibitors. |
| AID588499 | High-throughput multiplex microsphere screening for inhibitors of toxin protease, specifically Botulinum neurotoxin light chain A protease, MLPCN compound set | 2010 | Current protocols in cytometry, Oct, Volume: Chapter 13 | Microsphere-based flow cytometry protease assays for use in protease activity detection and high-throughput screening. |
| AID588499 | High-throughput multiplex microsphere screening for inhibitors of toxin protease, specifically Botulinum neurotoxin light chain A protease, MLPCN compound set | 2006 | Cytometry. Part A : the journal of the International Society for Analytical Cytology, May, Volume: 69, Issue:5 | Microsphere-based protease assays and screening application for lethal factor and factor Xa. |
| AID588499 | High-throughput multiplex microsphere screening for inhibitors of toxin protease, specifically Botulinum neurotoxin light chain A protease, MLPCN compound set | 2010 | Assay and drug development technologies, Feb, Volume: 8, Issue:1 | High-throughput multiplex flow cytometry screening for botulinum neurotoxin type a light chain protease inhibitors. |
| AID1745845 | Primary qHTS for Inhibitors of ATXN expression | |||
| AID977602 | Inhibition of sodium fluorescein uptake in OATP1B3-transfected CHO cells at an equimolar substrate-inhibitor concentration of 10 uM | 2013 | Molecular pharmacology, Jun, Volume: 83, Issue:6 | Structure-based identification of OATP1B1/3 inhibitors. |
| AID18526 | Observed pseudo-first order rate constant | 1989 | Journal of medicinal chemistry, Mar, Volume: 32, Issue:3 | Evaluation of glycolamide esters and various other esters of aspirin as true aspirin prodrugs. |
| AID15845 | Percentage of aspirin formed during hydrolysis in 10% human plasma at pH 7.4 at 37 degrees celsius | 1989 | Journal of medicinal chemistry, Mar, Volume: 32, Issue:3 | Evaluation of glycolamide esters and various other esters of aspirin as true aspirin prodrugs. |
| AID17241 | Observed second order rate constant | 1989 | Journal of medicinal chemistry, Mar, Volume: 32, Issue:3 | Evaluation of glycolamide esters and various other esters of aspirin as true aspirin prodrugs. |
| AID977599 | Inhibition of sodium fluorescein uptake in OATP1B1-transfected CHO cells at an equimolar substrate-inhibitor concentration of 10 uM | 2013 | Molecular pharmacology, Jun, Volume: 83, Issue:6 | Structure-based identification of OATP1B1/3 inhibitors. |
| AID25694 | t1/2 in 10% human plasma | 1989 | Journal of medicinal chemistry, Mar, Volume: 32, Issue:3 | Evaluation of glycolamide esters and various other esters of aspirin as true aspirin prodrugs. |
| AID540299 | A screen for compounds that inhibit the MenB enzyme of Mycobacterium tuberculosis | 2010 | Bioorganic & medicinal chemistry letters, Nov-01, Volume: 20, Issue:21 | Synthesis and SAR studies of 1,4-benzoxazine MenB inhibitors: novel antibacterial agents against Mycobacterium tuberculosis. |
| AID588519 | A screen for compounds that inhibit viral RNA polymerase binding and polymerization activities | 2011 | Antiviral research, Sep, Volume: 91, Issue:3 | High-throughput screening identification of poliovirus RNA-dependent RNA polymerase inhibitors. |
| AID1159607 | Screen for inhibitors of RMI FANCM (MM2) intereaction | 2016 | Journal of biomolecular screening, Jul, Volume: 21, Issue:6 | A High-Throughput Screening Strategy to Identify Protein-Protein Interaction Inhibitors That Block the Fanconi Anemia DNA Repair Pathway. |
| AID1159550 | Human Phosphogluconate dehydrogenase (6PGD) Inhibitor Screening | 2015 | Nature cell biology, Nov, Volume: 17, Issue:11 | 6-Phosphogluconate dehydrogenase links oxidative PPP, lipogenesis and tumour growth by inhibiting LKB1-AMPK signalling. |
| [information is prepared from bioassay data collected from National Library of Medicine (NLM), extracted Dec-2023] | ||||
| Timeframe | Studies, This Drug (%) | All Drugs % |
|---|---|---|
| pre-1990 | 4 (21.05) | 18.7374 |
| 1990's | 1 (5.26) | 18.2507 |
| 2000's | 4 (21.05) | 29.6817 |
| 2010's | 9 (47.37) | 24.3611 |
| 2020's | 1 (5.26) | 2.80 |
| [information is prepared from research data collected from National Library of Medicine (NLM), extracted Dec-2023] | ||
According to the monthly volume, diversity, and competition of internet searches for this compound, as well the volume and growth of publications, there is estimated to be very strong demand-to-supply ratio for research on this compound.
| This Compound (55.66) All Compounds (24.57) |
| Publication Type | This drug (%) | All Drugs (%) |
|---|---|---|
| Trials | 1 (5.26%) | 5.53% |
| Reviews | 3 (15.79%) | 6.00% |
| Case Studies | 0 (0.00%) | 4.05% |
| Observational | 0 (0.00%) | 0.25% |
| Other | 15 (78.95%) | 84.16% |
| [information is prepared from research data collected from National Library of Medicine (NLM), extracted Dec-2023] | ||